Compare Extra Space Storage, Inc. (EXR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Extra Space Storage, Inc. trades at $135.18 (market cap $28.26B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Extra Space Storage, Inc. is far larger — about 28.9× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Extra Space Storage, Inc. pays a 4.85% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| EXR | MRVI | |
|---|---|---|
Market Cap | $28.26B | $977.37M |
Volume | 1,443,466 | 2,742,564 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $9.00 |
52-Week Low | $126.67 | $2.83 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $41.97B | $1.08B |
Dividend Yield | 4.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $133.74, down 0.23% today, with neutral technical signals and mixed analyst sentiment. The REIT shows strong fundamentals with consistent revenue growth from $3.3B (2024) to $3.4B (2025) and robust profitability (28.83% net margin). Recent quarters have seen earnings beats, with Q3 2026 results expected October 27, 2026. The company maintains solid operational performance with 94.2% same-store occupancy and recently announced leadership transition effective January 2027.
EXR presents a balanced risk-reward profile with 50% analyst buy ratings and $158.33 consensus price target (18% upside). Strengths include scale, diversified growth, and financial flexibility, while risks involve softer housing activity impact and elevated debt levels (46.63% debt-to-asset ratio). The stock offers income potential with $1.62 quarterly dividend, but investors should monitor interest rate sensitivity and competitive pressures in the self-storage sector.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
